View Section: Eyestock Rating
Horizon Therapeutics Fair Value
HP
HPR.SW stock is not valued by Eyestock.
Historical price or reporting data is not enough to analyze the value of the company
Discover Undervalued Companies
Horizon Therapeutics Valuation
The fair value level of 73.67 CHF can be considered as an effective entry point for long-term investors to start investing in HPR.SW stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
1y
3y
5y
All time
Market price
Current market price
Fair value
Min value
Max value
15.11.2024
Market price:
* Eyestock is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on eyestock.io represent a recommendation to buy or sell a security.
Horizon Therapeutics PLC price metrics
41.56
Annual return (geometric mean)
42.89
Risk (standard deviation) of returns
β
0.21
Beta (volatility compared to market)
It means that HPR.SW stock is less volatile than the broader market
View Section: Profitability